Royalty Report: Drugs, Diagnostic, Disease – Collection: 239004

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Diagnostic
  • Disease
  • Therapeutic
  • Diabetes Treatment
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 239004

License Grant
The Parties wish to collaborate in the research and development of new protein, antibody and macromolecular therapeutics directed to human diseases, including, but not limited to, hematopoietic and inflammatory diseases,

Licensor grants to the Licensee of Japan and its Affiliates a non-exclusive right and license, without a right to grant sublicenses, under the Licensor Technology and Improvements, a worldwide, solely to conduct Licensees obligations to perform the R&D Work in accordance with the R&D Plan; and, in the Licensee Territory to make, use, sell, offer for sale and import New Products in the Licensee Territory; and in the Other Territory to make, use, sell, offer for sale and import New Products in the Other Territory.

Licensor grants to Licensee and its Affiliates, on a Development Candidate-by-Development Candidate basis, a worldwide co-exclusive right and license, exclusive except for Licensors retention of all such rights for itself and its Affiliates and its Sublicensees, under all Patent Rights of Licensor that claim each Development Candidate, including without limitation, the Prior Art Inventions, to make, use and import Development Candidates for the limited purpose of conducting the R&D Work in accordance with the R&D Plan.

Licensor grants to Licensee and its Affiliates, on a New Product-by-New Product basis, an exclusive right and license, under all Patent Rights of Licensor that claim each New Product. to make, use, sell, offer for sale and import New Products in the Licensee Territory and, solely as directed in the Other Territory.

Licensor assigns and agrees to assign to Licensee a one-half undivided interest, and thereby retains an equal one-half undivided interest, in, to and under any Joint Invention or Other Joint Invention made solely by the employees, agents or contractors of Licensor and its Affiliates; and, all Patent Rights claiming such Joint Invention or Other Joint Inventions.

License Property
The technology relates to Gene cloning and antibody development.

Inventions means any and all creations, materials and information. in any tangible or intangible form whatsoever and whether or not patentable, relevant to or resulting from the research, discovery, development, manufacture or commercialization of protein or antibody therapeutics or diagnostics, including, without limitation, ideas, discoveries, inventions, practices, methods, techniques, specifications, formulations, formulas, knowledge, trade secrets, know-how, skill, experience, test data (including pharmacological, biological, chemical, biochemical, toxicological and clinical test data), analytical and quality control data, stability data, results of studies, databases, technical drawings, software, works of authorship and other related subject matter.

Joint Invention means any Invention made in the course of performance of the R&D Work or commercialization of a New Product,  by one or more employees, agents or contractors of Licensor or its Affiliates and/or Licensee or its Affiliates, and, which comprises, or which is required to make, use, sell, offer for sale or import, a Development Candidate or a New Product.

Other Joint Invention means any Invention made in the course of performance of the R&D Work or commercialization of New Products by the employees, agents or contractors of Licensor or its Affiliates and/or Licensee or its Affiliates but excluding Joint Inventions, Licensor Improvements, and Licensee Improvements.

Field of Use
The developments are directed to human diseases, including, but not limited to, hematopoietic and inflammatory diseases.

IPSCIO Record ID: 239607

License Grant
The Parties wish to collaborate in the research and development of new protein, antibody and macromolecular therapeutics directed to human diseases, including, but not limited to, hematopoietic and inflammatory diseases.

Japanese Licensor grants to Licensee and its Affiliates a non-exclusive right and license, without a right to grant sublicenses, under the Licensor Technology and Licensor Improvements, as follow a worldwide, solely to conduct Licensees obligations to perform the R&D Work in accordance with the R&D Plan; in the Licensee Territory to make, use, sell, offer for sale and import New Products in the Licensee Territory; and in the Other Territory to make, use, sell, offer for sale and import New Products in the Other Territory.

Licensor grants to Licensee and its Affiliates, on a Development Candidate-by-Development Candidate basis, a worldwide co-exclusive right and license, exclusive except for Licensors retention of all such rights for itself and its Affiliates and its Sublicensees, under all Patent Rights of Licensor that claim each Development Candidate, induding without limitation, the Prior Art Inventions, to make, use and import
Development Candidates for the limited purpose of conducting the R&D Work in accordance with the R&D Plan.

Licensor grants to Licensee and its Affiliates, on a New Product-by-New Product basis. an exclusive right and license, under all Patent Rights of Licensor that claim each New Product, to make, use, sell, offer for sale and import New Products in the Licensee Territory and, solely as directed in the Other Territory.

Licensor assigns and agrees to assign to Licensee a one-half undivided interest, and thereby retains an equal one-half undivided interest, in, to and under any Joint Invention or Other Joint Invention made solely by the employees, agents or contractors of Licensor and its Affiliates; and, all Patent Rights claiming such Joint Invention or Other Joint Invention.

License Property
The technology relates to Gene cloning and antibody development.

Inventions means any and all creations, materials and information. in any tangible or intangible form whatsoever and whether or not patentable, relevant to or resulting from the research, discovery, development, manufacture or commercialization of protein or antibody therapeutics or diagnostics, including, without limitation, ideas, discoveries, inventions, practices, methods, techniques, specifications, formulations, formulas, knowledge, trade secrets, know-how, skill, experience, test data (including pharmacological, biological, chemical, biochemical, toxicological and clinical test data), analytical and quality control data, stability data, results of studies, databases, technical drawings, software, works of authorship and other related subject matter.

Joint Invention means any Invention made in the course of performance of the R&D Work or commercialization of a New Product,  by one or more employees, agents or contractors of Licensor or its Affiliates and/or Licensee or its Affiliates, and, which comprises, or which is required to make, use, sell, offer for sale or import, a Development Candidate or a New Product.

Other Joint Invention means any Invention made in the course of performance of the R&D Work or commercialization of New Products by the employees, agents or contractors of Licensor or its Affiliates and/or Licensee or its Affiliates but excluding Joint Inventions, Licensor Improvements, and Licensee Improvements.

Field of Use
The developments are directed to human diseases, including, but not limited to, hematopoietic and inflammatory diseases.

IPSCIO Record ID: 204233

License Grant
Development License.   Licensor hereby grants to Japanese Licensee an exclusive license, with the right to grant sublicenses, under the Licensor Patents, Licensor Know-How and Licensor’s interests in the Joint Patents and Joint Know-How to Develop the Products in accordance with the Development Plan and Joint Development Plan(s) in the Licensee Territory solely for purposes of obtaining Marketing Approval for use of the Product in the Field in the Licensee Territory.

Manufacturing License.  Licensor hereby grants to Licensee a worldwide non-exclusive license under the Licensor Patents, Licensor Know-How and Licensor’s interests in the Joint Patents and Joint Know-How to (i) Manufacture and have Manufactured Binimetinib and Encorafenib for use in the Manufacture of Products, and (ii) Manufacture and have Manufactured Products, in each case for use in Developing and Commercializing such Products in accordance with the rights and license granted to Licensee.  The licenses granted may be sublicensed by Licensee only to its Affiliates, and then only for so long as such entities remain as Affiliates. For clarity, the licenses granted may be extended by Licensee to Third Party manufacturers for Manufacturing the Products on Licensee’s behalf.

Commercialization License.  Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses and appoint distributors as provided, under the Licensor Patents, Licensor Know-How Development License.  Subject to the terms and conditions of this Agreement, including without limitation Licensor’s retained rights, Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses as provided, under the Licensor Patents, Licensor Know-How and Licensor’s interests in the Joint Patents and Joint Know-How to Develop the Products in accordance with the Development Plan and Joint Development Plan(s) in the Licensee Territory solely for purposes of obtaining Marketing Approval for use of the Product in the Field in the Licensee Territory.

License Property
Patent(s) means any patents and patent applications, together with all additions, divisions, continuations, continuations-in-part, substitutions, reissues, re-examinations, registrations, patent term extensions, supplemental protection certificates, and renewals of any of the foregoing.

Product means shall mean any pharmaceutical product containing, as an active ingredient, one or more of Binimetinib or Encorafenib, including, without limitation, any Combination Product.

Product Trademarks means: (a) the product-specific trademarks owned or Controlled by Licensor and designated by Licensor for use with Products containing Binimetinib, (b) the product-specific trademarks owned or Controlled by Licensor and designated by Licensor for use with Products containing Encorafenib, and (c) any other product-specific trademark(s) and service mark(s) as may be proposed by either Party and reviewed by the JCC for use in connection with the distribution, marketing, promotion and sale of a Product in the Licensee Territory, or accompanying logos, trade dress or indicia of origin.

Licensor Know-How means, all scientific, medical, technical, manufacturing, marketing, regulatory, market access and other information (including clinical data and other related information generated in compliance with CDISC (Clinical Data Interchange Standards Consortium) standards) relating to Binimetinib, Encorafinib, a Product and/or any Companion Diagnostic useful with respect to the Development, Manufacturing, registration (including registration for MAA) or Commercialization of a Product (including the Data), to the extent Controlled by Licensor or its Controlled Affiliates as of the Effective Date or during the term of this Agreement, and needed by or reasonably useful to Licensee in order for Licensee to exercise its rights or perform its obligations under this Agreement.  Licensor Know-How shall in any case include all such items that are generated by or under authority of Licensor, or any of its Affiliates, in connection with Development Manufacturing, and/or Commercialization of the Product during the term of this Agreement.

Binimetinib means the compound known as MEK162, the chemical structure as well as all salts, non-covalent complexes, hydrates, solvates, chelates, crystal polymorph or radiolabeled equivalent thereof.

Encorafenib means the compound known as LGX818, the chemical structure as well as all salts, non-covalent complexes, hydrates, solvates, chelates, crystal polymorph, or radiolabeled equivalent thereof.

Joint Inventions means all inventions arising during the term of the Agreement that (a) are jointly created or reduced to practice by employees, consultants, or contractors of Licensor or its Affiliates and by employees, consultants, or contractors of Licensee or its Affiliates, and (b) relate to Binimetinib, Encorafenib and/or Products.

Joint Know-How means all know-how arising during the term of the Agreement that (a) is jointly generated by employees, consultants, or contractors of Licensor or its Affiliates and by employees, consultants, or contractors of Licensee or its Affiliates, and (b) relates to Binimetinib, Encorafenib and/or Products.

Joint Patent means a Patent that covers or claims a Joint Invention

Field of Use
This agreement pertains to the drug industry.  Field means the diagnosis, treatment and/or prevention of diseases and conditions in humans.

Binimetinib is a MEK inhibitor being developed to treat various cancers.
Encorafenib, also known as LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase.

'These two compounds have shown promising efficacy and safety in the previous clinical trials and we believe that both compounds can be a new therapeutic option as a combination therapy for patients with BRAF-mutant melanoma, BRAF-mutant colorectal cancer and beyond.'

IPSCIO Record ID: 203487

License Grant
Licensor hereby grants to Licensee a worldwide exclusive right and license under the Licensor Patent Rights, the Licensor Know-How, and Licensors rights in the Joint Patent Rights and the Joint Know-How, to make, have made, use, have used, sell, distribute, offer for sale and import Licensed Products in the Licensed Field. In addition, Licensor hereby grants to Licensee a worldwide nonexclusive right and license to use Licensors Materials and Information to the extent and only to the extent necessary to develop and commercialize Licensed Products in the Licensed Field.
License Property
Licensed Product shall mean any product that contains a Properdin Antibody, or any service that utilizes a Properdin Antibody.

Licensor Patent Rights shall mean, collectively, (a) all patents and patent applications listed and any foreign counterparts claiming priority therefrom; (b) all patent applications heretofore or hereafter filed in any country which claim (and only to the extent they claim) the Licensor Materials and Information or the use thereof; (c) all patents that have issued or in the future issue from any of the foregoing patent applications, including without limitation utility, model and design patents and certificates of invention; and (d) all divisionals, continuations, continuations-in-part,reissues, reexamination certificates or renewals from, extensions of or additions to any such patents or patent applications. Notwithstanding the foregoing, Licensor Patent Rights shall not include any Patent Rights that are within the Licensee Patent Rights, the Joint Patent Rights or the Properdin Antibody Patent Rights.

Patent Application Pending: US 09/138,723

Licensor Know-How shall mean all Know-How developed or acquired by Licensor solely or jointly with a Third Party that is related to Properdin Antibodies.

Joint Patent Rights shall mean all Patent Rights that claim Joint Inventions.

Joint Know-How shall mean Know-How developed or acquired jointly by employees or agents of both Licensor and Licensee as a result of their collaboration under the 1999 Agreement or under this Agreement; provided that such Know-How does not include subject matter within the Licensee Materials and Information, the Licensor Materials and Information or the Properdin Antibody Materials and Information.

Licensor Materials and Information shall mean, collectively, (a) the Antigen; (b) all reagents, samples and other chemical or biological materials regarding the Antigen which resulted or is otherwise derived from use of the Antigen under the 1999 Agreement or which results or is otherwise derived from use of the Antigen under this Agreement; and (c) all information (and all tangible and intangible embodiments thereof) regarding the foregoing, irrespective of inventorship, which is disclosed by Licensor to Licensee hereunder or which resulted or is otherwise derived from use of the Antigen under the 1999 Agreement or which results or is otherwise derived from use of the Antigen pursuant to this Agreement. Notwithstanding the foregoing, Licensor Materials and Information shall not include subject matter within the Licensee Materials and Information or the Properdin Antibody Materials and Information.

Field of Use
Acquiring right relates to the development and commercialization of anti-properdin antibody therapies.  An anti-properdin antibody may be a potential treatment for cardiovascular or inflammatory disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.